Why does your joint feel better one day and worse the next?

What makes the ache rise and fall?

Each activity puts a different amount of pressure on the joint. Level ground may feel fine while a slope brings knee soreness. Sitting may calm a hip, yet standing afterward can feel stiff. Light reaching may be comfortable until work goes over the head. Long periods in one position can also add stiffness.

The key question is which activity came before the soreness rose.

Keep the same short notes for several days. Record the time spent walking, standing, driving, or reaching. Add whether the ache disturbed sleep. A long diary isn't needed. A few exact details help more than a general score.

Judge any home step or treatment while activity stays about the same. A drop in soreness proves little after a much quieter week. Look for easier movement during the same task. Also notice whether that change lasts beyond one good day.

Usual soreness may move up and down within a familiar range. A new problem may feel sharper, swell faster, or stop a task that was possible before. Tell your own doctor when the change is outside that normal range. The exam can then focus on what changed.

Choose one clear goal, such as walking farther or sleeping longer. Progress means that the chosen task becomes easier without a larger flare later. That is clearer than saying the joint feels somewhat better.

In short, compare the same activity and watch for a lasting change.

Sources

1. A meta-analysis of 14 placebo cohorts across 13 Level I trials in 1,076 knee osteoarthritis patients found that intra-articular saline - the placebo - produced pain and function improvements exceeding the minimal clinically important difference at 3 and 6 months.

   Saltzman BM, et al. — The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies. Am J Sports Med, 2017. DOI: 10.1177/0363546516680607.

2. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

3. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

4. A controlled randomized phase I/II trial in 26 patients found repeated dosing of culture-expanded umbilical cord-derived MSCs at baseline and 6 months produced lower WOMAC pain at 12 months (1.1 +/- 1.3) than hyaluronic acid (4.3 +/- 3.5), while a single MSC dose did not separate from hyaluronic acid.

   Matas J, et al. — Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial. Stem Cells Transl Med, 2019. DOI: 10.1002/sctm.18-0053.

5. A phase IIb double-blind randomized trial of just 24 knees reported WOMAC improvement at 6 months after a single autologous adipose-derived MSC injection while saline controls did not improve - a positive but very small trial, of the kind that dominates this literature.

   Lee WS, et al. — Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, Placebo-Controlled Clinical Trial. Stem Cells Transl Med, 2019. DOI: 10.1002/sctm.18-0122.